BioCryst Pharmaceuticals (NASDAQ:BCRX) has agreed to acquire biopharmaceutical firm Astria Therapeutics (NASDAQ:ATXS) for a mix of cash and stock representing an implied value of $13.00 per Astria share, and around $700 million in enterprise value.
The implied $13.00 value of the